In this episode, Ben sits down with Asa Abeliovich, MD, PhD, Founder and CEO of Leal Therapeutics, to talk about Leal’s mission to develop precision medicines for some of the most complex and underserved neurodegenerative diseases.

The conversation explores how Leal is using human genetics, disease biology, and translational neuroscience to build a pipeline focused on conditions such as Parkinson’s disease, Alzheimer’s disease, and ALS. Asa discusses the rationale behind Leal’s approach, the importance of selecting the right biological targets, and the challenges of turning genetic insight into therapies that can meaningfully impact patients.

We also discuss Asa’s broader experience as a neurologist, neuroscientist, and biotech founder, including lessons from building companies in areas where clinical development remains exceptionally difficult.

A thoughtful discussion on Leal Therapeutics, precision neuroscience, and what it takes to advance new treatment strategies in neurodegeneration.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Max Brennan - Biotech HeadHunter. Innehållet i podden är skapat av Max Brennan - Biotech HeadHunter och inte av, eller tillsammans med, Poddtoppen.